Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMG 193 (Primary) ; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib
Indications Non-small cell lung cancer; Thoracic neoplasms
Focus Adverse reactions
Sponsors Amgen

27 Dec 2024 Planned End Date changed from 25 Oct 2031 to 27 Oct 2031.
27 Dec 2024 Planned primary completion date changed from 25 Oct 2028 to 27 Oct 2028.
06 Dec 2024 Planned End Date changed from 16 Jun 2032 to 25 Oct 2031.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com